<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247194</url>
  </required_header>
  <id_info>
    <org_study_id>PPI-461-102</org_study_id>
    <secondary_id>2010-021510-36</secondary_id>
    <nct_id>NCT01247194</nct_id>
  </id_info>
  <brief_title>A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1</brief_title>
  <official_title>A Phase 1b Study to Assess the Safety, Antiviral Efficacy and Pharmacokinetics of PPI-461 in Patients With HCV Genotype-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Presidio Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Presidio Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety, tolerability, antiviral effects, and
      pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability, as measured by clinical adverse events and laboratory assessments</measure>
    <time_frame>up to Study Day 16 (14 days after the last PPI-461 dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral effects of PPI-461, as measured by HCV RNA levels</measure>
    <time_frame>Up to Study Day 16 (14 days after the last PPI-461 dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PPI-461 pharmacokinetics as measured by plasma PPI-461 concentrations</measure>
    <time_frame>Up to Study Day 10 (8 days after the last PPI-461 dose)</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Chronic Genotype 1 Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PPI-461 50 mg
or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PPI-461 100 mg
or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PPI-461 200 mg
or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPI-461</intervention_name>
    <description>capsule, oral, once daily for 3 days</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>capsules, oral, once daily for 3 days</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:

          -  Male or female, between 18 and 65 years of age (female patients must be surgically
             sterile or 2 years post-menopausal and are required to take a pregnancy test)

          -  Body Mass Index (BMI) 18 - 32 kg/m2

          -  Chronically infected with hepatitis C genotype-1 virus

          -  Serum HCV RNA &gt; 5 log10 IU/mL

          -  No previous treatment with interferon, peginterferon, ribavirin or any investigational
             HCV antiviral agents

          -  No history of signs or symptoms of decompensated liver disease

          -  No known history of cirrhosis

          -  No co-infection with HBV, HIV-1, HIV-2

          -  No history of any medical condition that may interfere with absorption, distribution
             or elimination of study drug or with the clinical and laboratory assessments in this
             study

          -  No history of alcohol abuse, or illicit drug use within 2 years prior to Screen, or
             enrollment in a methadone maintenance program (unless he/she has been enrolled in the
             methadone program for at least 3 months with good compliance, stable psychosocial
             circumstances, and no known current risks for recidivism)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathaniel Brown, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Presidio Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>Kolding</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local institution</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <last_update_submitted>February 1, 2012</last_update_submitted>
  <last_update_submitted_qc>February 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <keyword>NS5A</keyword>
  <keyword>HCV RNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

